COHERUS BIOSCIENCES INC. - COMMON STOCK

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

14 10 2024 14:55:18 提供 NetDania Notify

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

11 10 2024 11:33:36 提供 NetDania Notify

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

10 10 2024 14:23:54 提供 NetDania Notify

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

23 9 2024 11:26:09 提供 NetDania Notify

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

16 9 2024 09:48:41 提供 NetDania Notify

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

19 8 2024 14:06:12 提供 NetDania Notify

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

08 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

07 8 2024 14:09:32 提供 NetDania Notify

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

05 8 2024 09:45:04 提供 NetDania Notify

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

01 8 2024 09:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

08 7 2024 09:58:08 提供 NetDania Notify

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

05 7 2024 09:50:52 提供 NetDania Notify

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

03 7 2024 09:46:52 提供 NetDania Notify

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

02 7 2024 11:28:48 提供 NetDania Notify

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

27 6 2024 08:26:59 提供 Nasdaq GlobeNewswire

Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

05 6 2024 09:00:00 提供 Nasdaq GlobeNewswire

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

30 5 2024 09:00:00 提供 Nasdaq GlobeNewswire

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 5 2024 17:51:06 提供 Nasdaq GlobeNewswire

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

23 5 2024 09:00:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

09 5 2024 16:01:00 提供 Nasdaq GlobeNewswire